University Hospitals Coventry and Warwickshire NHS Trust on behalf of the Coventry and Warwickshire Integrated Care System; George Elliot Hospital NHS Trust and South Warwickshire University NHS Foundation Trust and Warwick Hospitals

Project Name: Coventry and Warwickshire Integrated Care System Secondary prevention ASCVD pharmacist led service

Project Summary:

The main objective of the CWP is to improve the quality of care for patients treated for Atherosclerotic Cardiovascular Disease (ASCVD) within Coventry and Warwickshire Integrated Care System (ICS) specifically acute coronary syndrome (ACS), with a particular focus on long term risk factor management and the transition of care between secondary and primary care who are at high risk of cardiovascular events or experienced a cardiac event  and who are not achieving lipid levels as specified in national and/or local guidance, in response to the needs of the CW Partner. This will be achieved by implementing and adopting the Accelerated Access Collaborative (AAC) guidelines across the ICS alongside the standardisation of the cardiac rehab services across the integrated Care System (ICS) and through the development of a cardiac rehab services at South Warwickshire University foundation trust (SWFT) and George Eliot Hospital NHS Trust (GEH) that will mirror the established cardiac rehab service at UHCW.

The secondary objective is to reduce the current backlog of patients waiting to be seen (2 months) by the UHCW lipid service by implementing a local secondary care led secondary prevention clinic, focusing on supporting the discharge and onward management of secondary prevention patients, including first dose medicine optimisation, and subsequent transfer to primary care setting.

This will be achieved by the funding for an additional Clinical Pharmacist Band 8A to develop and support a lipid optimisation service offered by the current lipid service and cardiac rehab departments across the ICS.

Project Amendment

The project is to be extended for an additional period of 3 months, starting from December 2024 and ending in March 2025. This extension is necessary for the following reasons:

1. There was a delay of circa 12 weeks in the pharmacist obtaining an honorary contract for the planned activity at George Eliot Hospital NHS Trust (GEH) and south Warwickshire University foundation trust and as a result, only 9 months of clinical data will have been captured from the activity at GEH and SwFT (as of November 2024)
2. A full 12 month data set is required for the CWP’s business case, a key milestone and deliverable for this project and its future sustainability.
    

This amendment will mean that at the end of this project a full 12-month data set can be captured, ensuring equitable activity across both South Warwickshire University FT (SWFT) and GEH. An additional 3 months data set will be gathered totaling 15 months from UHCW. The data collected during this extension will support a more robust business case as stated in the CWP (Clinical Workforce Plan).

During the period of delay in issuing the honorary contract, the pharmacist continued to work at full capacity at UHCW. The task of setting up the clinics (including establishing clinical space, gaining approval of clinic protocols) as well as clinical delivery, took longer than anticipated therefore the extended financial contributions remain set at full-time rates. 

Planned Milestones:

Expected Benefits:

ANTICIPATED BENEFITS FOR PATIENTS

• Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.   
• Enhanced experience around ASCVD with ongoing management of the condition.   
• Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events.  
• Easier access to lipid management care closer to home in the Primary Care setting coordinated by secondary care.
• The additional capacity will provide additional time and support from PCN HCP with their lipid management, focusing on patients who may have previously not attended GP appointment or been lost to follow-up.

ANTICIPATED BENEFITS FOR THE ORGANISATION(S)

• Increased proportion of ASCVD patients reviewed. 
• Increased proportion of ASCVD patients receiving expert and timely review closer to home  
• Reduction in ASCVD referral rates to secondary care  
• Increased proportion of patients receiving guideline-directed pharmacotherapy  
• Insight into benefits of primary care pharmacist led lipid management clinics in primary care   
• Support aligned to NHS Long Term Plan, CVDPREVENT, and Network Contract DES 

ANTICIPATED BENEFITS FOR NOVARTIS

• Insight on the use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicine , where appropriate.
• Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life, by supporting high quality Collaborative Working with healthcare organisations which addresses the problem of health inequalities    
• Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation

Start Date & Duration: October 2023 for 13 months

Amended Contract extended for 3 months from December 2024 to March 2025

FA-11326363 | November 2024